Dublin, Sept. 09, 2021 (GLOBE NEWSWIRE) -- The "Global Next-Generation Sequencing Data Analysis Market Size, Share & Trends Analysis Report by Product, by Workflow, by Mode, by Read Length, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
The global next-generation sequencing data analysis market size is expected to reach USD 1.72 billion by 2028 registering a CAGR of 15.02%.
Key drivers contributing to market expansion include the growing adoption of sequencing platforms for clinical diagnosis because of a significant reduction in the cost of installation. The easy availability of genomic and proteomic data is also expected to create lucrative growth opportunities in this market during the forecast period.
In addition, a decrease in the cost of sequencing is expected to increase the adoption of next-generation sequencing (NGS), which, in turn, is likely to boost the market growth. Availability of tools, such as Agilent's HaloPlex capture system and Targeted Methyl-Seq platform from EpiGentek Group Inc., has helped in the determination of DNA methylation profiles in individual genomes. An increase in the adoption of bisulfite-methylation for targeted sequencing and targeted methylation NGS data analysis methods is anticipated to propel market growth.
EpigenDx, CD Genomics, Novogene Co., Ltd., and Epigentek Group, Inc. are the key players that offer methylation sequencing and targeted bisulfite sequencing data analysis services. The launch of new products will further boost revenue generation in the market. Major market participants have undertaken various strategic initiatives to strengthen their position in the market. For instance, in January 2021, Transnetyx, Inc. collaborated with One Codex to provide end-to-end analysis and microbiome sequencing services. This is expected to offer affordable sequencing analysis services to researchers.
Next-Generation Sequencing Data Analysis Market Report Highlights
- Services dominated the products segment in 2020 and will retain the leading position growing at the fastest CAGR during the forecast period
- Although NGS is advantageous in terms of affordability and speed, many research entities are unable to adopt it owing to a lack of sufficient computational infrastructure and skilled professionals to analyze the generated information
- Therefore, institutions that lack provision for data interpretation, analysis, and management adopt platforms & services offered by other companies in the market
- Tertiary analysis occupied a major portion of the revenue generated by the workflow segment as it accounts for the most complex and important step of Next-Generation Sequencing, which is directly linked with the interpretation of results
- In-house mode dominated the market in 2020 and is expected to maintain its dominance during the forecast period
- However, the outsourced mode is expected to register the fastest CAGR from 2021 to 2028 owing to the time and cost benefits associated with this mode and the presence of key players offering data analysis services
- The short-read sequencing segment led the global market in 2020 due to the wide adoption of these techniques as they are inexpensive and can work with fragment DNA along with the availability of several tools and algorithms
- The academic research end-use segment generated the largest revenue in 2020; however, clinical research is estimated to be the fastest-growing segment from 2021 to 2028
- North America dominated the global market in 2020 owing to the launch of large-scale genome sequencing projects and the rise in demand for personalized medicine
Key Topics Covered:
Chapter 1 NGS Data Analysis Market: Methodology and Scope
Chapter 2 NGS Data Analysis Market: Executive Summary
Chapter 3 NGS Data Analysis Market: Market Variables, Trends, and Scope
3.1 Market Trends and Outlook
3.2 Market Segmentation and Scope
3.3 Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Demand for efficient algorithms and tools for analysis of large amount of data generated by sequencers
3.3.1.2 Introduction of technological advancements in cloud computing and data integration
3.3.1.3 Increasing penetration of the NGS technology in personalized medicine and precision diagnosis
3.3.1.4 Rising academic research based on NGS protocols
3.3.2 Market restraint analysis
3.3.2.1 Challenges in sequence compression and data storage
3.3.2.2 Selection of appropriate algorithms and Parallelizing scientific workflows
3.3.2.3 Budget and time constraints
3.4 Next generation sequencing data analysis company heat map analysis, 2019
3.4.1 Company size
3.4.2 Geographical presence
3.4.3 Product portfolio
3.4.4 Strategic initiatives
3.5 Business Environment Analysis
3.5.1 SWOT analysis; by factor (political & legal, economic and technological)
3.5.2 Porter's Five Forces Analysis
3.6 Penetration and Growth Prospect Mapping for Workflow, 2020
Chapter 4 NGS Data Analysis Market: Product Estimates and Trend Analysis
4.1 Market: Product Movement Analysis
4.2 NGS Data Analysis Services
4.2.1 Market, 2017 - 2028 (USD Million)
4.3 NGS Commercial Software
4.3.1 Market, 2017 - 2028 (USD Million)
4.3.2 Platform OS/UI
4.3.2.1 Market, 2017 - 2028 (USD Million)
4.3.3 Analytical software
4.3.3.1 Market, 2017 - 2028 (USD Million)
4.3.3.2 Alignment tools & software
4.3.3.2.1 Market, 2017 - 2028 (USD Million)
4.3.3.2.2 DNA sequencing Alignment
4.3.3.2.2.1 Market, 2017 - 2028 (USD Million)
4.3.3.2.3 RNA sequence alignment
4.3.3.2.3.1 Market, 2017 - 2028 (USD Million)
4.3.3.2.4 Protein sequence alignment
4.3.3.2.4.1 Market, 2017 - 2028 (USD Million)
4.3.3.3 QC/Pre-processing tools
4.3.3.3.1 Market, 2017 - 2028 (USD Million)
4.3.3.4 Others
4.3.3.4.1 Market, 2017 - 2028 (USD Million)
Chapter 5 NGS Data Analysis Market: Workflow Business Analysis
5.1 NGS Data Analysis Market: Workflow Movement Analysis
5.2 Primary Data NGS Analysis
5.2.1 Market, 2017 - 2028 (USD Million)
5.3 Secondary Data Analysis
5.3.1 Market, 2017 - 2028 (USD Million)
5.3.2 Read mapping
5.3.2.1 Market, 2017 - 2028 (USD Million)
5.3.3 Variant alignment & variant calling
5.3.3.1 Market, 2017 - 2028 (USD Million)
5.4 Tertiary Data Analysis
5.4.1 Market, 2017 - 2028 (USD Million)
5.4.2 Variant annotation
5.4.2.1 Market, 2017 - 2028 (USD Million)
5.4.3 Application-specific data analysis
5.4.3.1 Market, 2017 - 2028 (USD Million)
5.4.3.2 Targeted sequencing/gene panel
5.4.3.2.1 Market, 2017 - 2028 (USD Million)
5.4.3.3 Exome sequencing
5.4.3.3.1 Market, 2017 - 2028 (USD Million)
5.4.3.4 RNA sequencing
5.4.3.4.1 Market, 2017 - 2028 (USD Million)
5.4.3.5 Whole genome sequencing
5.4.3.5.1 Market, 2017 - 2028 (USD Million)
5.4.3.6 ChIP-sequencing
5.4.3.6.1 Market, 2017 - 2028 (USD Million)
5.4.3.7 Others
5.4.3.7.1 Market, 2017 - 2028 (USD Million)
Chapter 6 NGS Data Analysis Market: Mode Estimates and Trend Analysis
6.1 NGS Data Analysis Market: Mode Movement Analysis
6.2 In-house Data Analysis
6.2.1 Market, 2017 - 2028 (USD Million)
6.3 Outsourced Data Analysis
6.3.1 Market, 2017 - 2028 (USD Million)
Chapter 7 NGS Data Analysis Market: Read Length Estimates and Trend Analysis
7.1 NGS Data Analysis Market: Read Length Movement Analysis
7.2 Short Read Sequencing
7.2.1 Market, 2017 - 2028 (USD Million)
7.3 Long Read Sequencing
7.3.1 Market, 2017 - 2028 (USD Million)
7.4 Very Long Read Sequencing
7.4.1 Market, 2017 - 2028 (USD Million)
Chapter 8 NGS Data Analysis Market: End-use business analysis
8.1 Market: End-use Movement Analysis
8.2 Academic Research
8.2.1 Market for academic research, 2017 - 2028 (USD Million)
8.3 Clinical Research
8.3.1 Market for clinical research, 2017 - 2028 (USD Million)
8.4 Hospitals & Clinics
8.4.1 Market for hospitals & clinics, 2017 - 2028 (USD Million)
8.5 Pharmaceutical & Biotech Entities
8.5.1 Market for pharmaceutical & biotech entities, 2017 - 2028 (USD Million)
8.6 Other Users
8.6.1 Market for other users, 2017 - 2028 (USD Million)
Chapter 9 NGS Data Analysis Market: Region Business Analysis
Chapter 10 NGS Data Analysis Market: Company Profile
10.1 Strategy Framework
10.2 Market Participation Categorization
10.3 Company Profiles
10.3.1 QIAGEN
10.3.1.1 Company overview
10.3.1.2 Financial Performance
10.3.1.3 Product benchmarking
10.3.1.4 Strategic initiatives
10.3.2 Illumina, Inc.
10.3.2.1 Company overview
10.3.2.2 Edico Genome
10.3.2.2.1Company overview
10.3.2.3 Financial performance
10.3.2.4 Product benchmarking
10.3.2.5 Strategic initiatives
10.3.3 F. Hoffmann-La Roche Ltd.
10.3.3.1 Company overview
10.3.3.2 Financial performance
10.3.3.3 Product benchmarking
10.3.3.4 Strategic initiatives
10.3.4 Thermo Fisher Scientific, Inc.
10.3.4.1 Company overview
10.3.4.2 Life Technologies Corp.
10.3.4.2.1Company overview
10.3.4.3 Financial performance
10.3.4.4 Product benchmarking
10.3.4.5 Strategic initiatives
10.3.5 Agilent Technologies, Inc.
10.3.5.1 Company overview
10.3.5.2 Financial performance
10.3.5.3 Product benchmarking
10.3.5.4 Strategic initiatives
10.3.6 Bio-Rad Laboratories, Inc.
10.3.6.1 Company overview
10.3.6.2 GnuBio
10.3.6.2.1Company overview
10.3.6.3 Financial performance
10.3.6.4 Product benchmarking
10.3.6.5 Strategic initiatives
10.3.7 PierianDX
10.3.7.1 Company overview
10.3.7.2 Tute Genomics
10.3.7.2.1 Company overview
10.3.7.2.2 Knome, Inc.
10.3.7.2.2.1 Company overview
10.3.7.3 Financial performance
10.3.7.4 Product benchmarking
10.3.7.5 Strategic initiatives
10.3.8 Intrexon Bioinformatics Germany GmbH
10.3.8.1 Company overview
10.3.8.2 Financial performance
10.3.8.3 Product benchmarking
10.3.8.4 Strategic initiatives
10.3.9 Partek Incorporated
10.3.9.1 Company overview
10.3.9.2 Financial performance
10.3.9.3 Product benchmarking
10.3.9.4 Strategic initiatives
10.3.10 Eurofins Scientific
10.3.10.1 Company overview
10.3.10.2 GATC Biotech GmbH
10.3.10.2.1 Company overview
10.3.10.3 Financial performance
10.3.10.4 Product benchmarking
10.3.10.5 Strategic initiatives
10.3.11 Pacific Biosciences Of California, Inc.
10.3.11.1 Company overview
10.3.11.2 Financial performance
10.3.11.3 Product benchmarking
10.3.11.4 Strategic initiatives
10.3.12 DNASTAR, Inc.
10.3.12.1 Company overview
10.3.12.2 Financial performance
10.3.12.3 Product benchmarking
10.3.12.4 Strategic initiatives
10.3.13 Congenica Ltd.
10.3.13.1 Company overview
10.3.13.2 Financial performance
10.3.13.3 Product benchmarking
10.3.13.4 Strategic initiatives
10.3.14 Fabric Genomics, Inc.
10.3.14.1 Company overview
10.3.14.2 Financial performance
10.3.14.3 Product benchmarking
10.3.14.4 Strategic initiatives
10.3.15 Genuity Science
10.3.15.1 Company overview
10.3.15.2 Product benchmarking
10.3.15.3 Strategic initiatives
10.3.16 DNANEXUS Inc.
10.3.16.1 Company overview
10.3.16.2 Financial performance
10.3.16.3 Product benchmarking
10.3.16.4 Strategic initiatives
10.3.17 Scigenom Labs Pvt. Ltd.
10.3.17.1 Company overview
10.3.17.2 Product benchmarking
10.3.17.3 Strategic initiatives
10.3.18 Golden Helix, Inc.
10.3.18.1 Company overview
10.3.18.2 Financial performance
10.3.18.3 Product benchmarking
10.3.18.4 Strategic initiatives
For more information about this report visit https://www.researchandmarkets.com/r/1xrqkx
